(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 92.6% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Immunome's revenue in 2025 is $9,679,000.On average, 14 Wall Street analysts forecast IMNM's revenue for 2025 to be $676,363,293, with the lowest IMNM revenue forecast at $620,144,893, and the highest IMNM revenue forecast at $957,271,871. On average, 14 Wall Street analysts forecast IMNM's revenue for 2026 to be $754,317,028, with the lowest IMNM revenue forecast at $0, and the highest IMNM revenue forecast at $2,561,468,037.
In 2027, IMNM is forecast to generate $7,529,138,611 in revenue, with the lowest revenue forecast at $539,256,429 and the highest revenue forecast at $20,836,574,934.